Biocon Biologics
Biocon Biologics, a subsidiary of Biocon Limited, is a leading player in the biopharmaceutical industry, headquartered in Bengaluru, India. Founded in 1978, the company has established itself as a pioneer in the development of biosimilars, insulin, and monoclonal antibodies, catering to a global market. With a strong focus on innovation, Biocon Biologics has achieved significant milestones, including the launch of several groundbreaking biosimilars that enhance patient access to affordable healthcare. The company operates extensively across major regions, including North America, Europe, and Asia, positioning itself as a trusted partner in the biopharmaceutical sector. Biocon Biologics is recognised for its commitment to quality and compliance, which has earned it a robust market position and numerous accolades in the industry. Its unique portfolio of products not only addresses critical therapeutic needs but also exemplifies the company's dedication to advancing healthcare solutions worldwide.
DitchCarbon Score
How does Biocon Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocon Biologics's score of 30 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biocon Biologics's reported carbon emissions
In 2023, Biocon Biologics reported significant carbon emissions, totalling approximately 165,000,000 kg CO2e. This figure includes 8,256,000 kg CO2e from Scope 1 emissions, 87,936,000 kg CO2e from Scope 2 emissions, and a substantial 156,387,000 kg CO2e from Scope 3 emissions. The following year, 2024, saw a slight increase in Scope 1 emissions to about 8,491,000 kg CO2e and a decrease in Scope 2 emissions to approximately 78,721,000 kg CO2e, but no Scope 3 data was disclosed for that year. Despite these emissions figures, Biocon Biologics has not publicly committed to specific reduction targets or initiatives, nor have they outlined any climate pledges. This lack of defined targets may reflect a broader industry context where many companies are still developing comprehensive climate strategies. As a leading biopharmaceutical company headquartered in India, Biocon Biologics is positioned to enhance its sustainability efforts in alignment with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 8,256,000 | 0,000,000 |
| Scope 2 | 87,936,000 | 00,000,000 |
| Scope 3 | 156,387,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocon Biologics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
